Mechanisms of Refractory Hypertension (Reserpine)

• Status: Completed
• Trial end date: 2020-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Reserpine

Criteria

Inclusion Criteria:

• adult with refractory hypertension defined as uncontrolled office blood pressure with use of 5 or more hypertensive agents, including a thiazide diuretic and spironolactone

Exclusion Criteria:

• congestive heart failure (EF 40%)

• chronic kidney disease (GFR <40 ml/min/1.73 mm)

• stroke and/or myocardial infarction or acute CHF exacerbation within last 3 months

• ongoing depression

• active peptic ulcer disease

• bradycardia <50 beats per minute

• 2nd or 3rd degree heart block

• known intolerance of reserpine

• use of digoxin or tricycle antidepressants